Novartis Halts ALS Drug Development After Phase 2 Trial Failure
Product·2 articles across 2 outlets
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Novartis AG halted development of an experimental drug it hoped would treat amyotrophic lateral sclerosis, or Lou Gehrig’s disease, the latest in a long history of failed efforts to find a cure for the deadly condition.
Novartis has extended its losing streak, stopping an amyotrophic lateral sclerosis program after flunking a phase 2 trial.
Novartis
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“Novartis AG halted development of an experimental drug it hoped would treat amyotrophic lateral sclerosis, or Lou Gehrig’s disease, the latest in a long history of failed efforts to find a cure for the deadly condition.”
Bloomberg — Novartis Experimental Drug for ALS Fails in Another Pipeline Hit“Novartis has extended its losing streak, stopping an amyotrophic lateral sclerosis program after flunking a phase 2 trial.”
fierce biotech — <a href="/biotech/novartis-ends-als-program-after-phase-2-flop-adding-rd-woes" hreflang="en">Novartis ends ALS program after phase 2 flop, adding to R&D woes</a>